peter-k-law
Peter K Law, PhD
Founder and Chairman

Cell Therapy Institute,
Huazhong University of Science and Technology,
Wuhan, China
E-mail: pdlaw888@yahoo.ca

Education

1958–July, 1963
1963–July, 1965
High school Maryknoll Fathers’ School
St. Stephen’s College
Hong Kong
1965–May 1968 Undergraduate B.Sc Honors Zoology,
McGILL University
-
Sept., 1968–Apr., 1969
Sept., 1969– Apr., 1972
Graduate school University of Toronto, M.Sc. (Neurophysiology)
University of Toronto, Ph.D
-
Sept., 1972–75 Post-doctorate McMaster University, Clinical Neurophysiology -

Biography

I have been a Canadian citizen and was a US permanent resident, with B.Sc (Hons.) from McGILL University, M.Sc., Ph.D. from the University of Toronto, and post-doctorate from McMaster University. I was an Assistant Professor of Neurology at Vanderbilt University, Associate and Full Professor with tenure of Neurology and Physiology/ Biophysics at the University of Tennessee, Memphis. In 1991, I found the non-profit Cell Therapy Research Foundation in USA to focus on clinical trials on muscular dystrophy (MD) using myoblasts.


Research Interest

Neurology, Physiology, Biophysics, Cell Therapy, muscular dystrophies, cancer, heart diseases, Type II diabetes and aging


Scientific Activities

Honors
  • Upon the recommendation of the Chinese Consulate General of the People’s Republic of China in Toronto, I was invited as a Premiere Scientist by the Ministry of Foreign Affairs and the Ministry of Central Organization to participate in a 4-day event in Beijing during the PRC’s 60th anniversary, including presiding over the military parade at Tian An Men Square, meeting and speaking in person with Chairman Hu Jing Tao, Premier Wen Jiabao and other leaders of China, and dinning with them in the Banquet Hall of the Great Hall of the People on Sept. 30, 2009.
  • Upon the recommendation of the Russian Academy of Medical Sciences, I collaborated with President Putin’s Cardiac Surgeons Academicians Leo Bockeria and Ilia Berishvili to conduct the world’s first myoblast allograft into the human heart in Moscow on January 17, 2003.
  • I was an invited speaker of the President of Trinidad/Tobago to brief on Heart Cell Therapy with Myoblasts on March 8, 2002.
  • I was a medical consultant for the family of H.R.H. Prince Mohammed Ben Hassan Al-Mohammed of Saudi Arabia in Washington DC on December 22, 2000.
  • Upon the recommendation of Mr. Richard Kelly, step-father of President Bill Clinton, I was invited to the White House of the USA to speak on Myoblast Transfer Therapy on Sept. 2, 1999 and was conferred the Distinguished Services Award of USA.
  • I was invited by President Mobaruk of Egypt to speak on the technology of Myoblast Transfer Therapy in the Nasser Institute in Cairo on May 10, 1997.
Awards
  • Charles A. Dana, Award nominee for pioneering achievement in Health
  • Muscular Dystrophy Association of Canada Post-doctoral Fellowship (Top priority rating)
  • University of Toronto Scholarship
  • National Research Council of Canada Scholarship
  • Ontario Graduate Fellowship
  • National Research Council of Canada Research Assistantship
  • McGILL Alumni Scholarship
  • St. Stephen’s Scholarship
  • Hong Kong Government Maintenance Grant
  • Maryknoll Fathers’ Scholarship
Society memberships
  • American Association of University Professors
  • American Association of Electromyography and Electrodiagnosis
  • American Academy of Clinical Neurophysiology
  • American Heart Association
  • American Physiological Society
  • Society for Neurosciences
  • American Association for the Advancement of Science
  • American Society for Neural Transplantation
  • New York Academy of Sciences
  • Association of American Medical Colleges
  • Southern EEG Society
  • International Society of Developmental and Comparative Immunology
  • Who’s Who in Frontier Science and Technology
  • Who’s Who in Executives and Professionals

Publications

  1. Law, P.K. and H.L. Atwood. Membrane resistance change induced by nitrate and other anions in long and short sarcomere muscle fibres of crayfish. Comp. Biochem. Physiol. 40A:265–271, 1971.
  2. Law, P.K. and H.L. Atwood. Sarcoplasmic resistivity of crayfish muscle fibres. Can. J. Zool. 49:1063–1074, 1971.
  3. Law, P.K. and H.L. Atwood. Non-equivalance of surgical and natural denervation in dystrophic mouse muscles. Exp. Neurol. 34:200–209, 1972.
  4. Law, P.K. and H.L. Atwood. Cross-reinnervation of dystrophic mouse muscles. Nature 238:287–288, 1972.
  5. Law, P.K. and H.L. Atwood. Does axonal sprouting occur in dystrophic mouse muscles? Experientia 30:155–156, 1974.
  6. Law, P.K. and M.R. Caccia. Physiological estimates of the sizes and number of motor units in soleus muscles of dystrophic mice. J. Neurol. Sci. 24:251–256, 1975.
  7. Law, P.K., E. Cosmos, J. Butler and A.J. McComas. The absence of dystrophic characteristics in normal muscles successfully cross-reinnervated by nerves of dystrophic genotypes: Physiological and cytochemical study of crossed solei of normal and dystrophic parabiotic mice. Exp. Neurol. 51: 1–21, 1976.
  8. Law, P.K., H.L. Atwood, and A.J. McComas. Functional denervation in dystrophic mouse muscles, Exp. Neurol. 51:434–443, 1976.
  9. Pomeranz, B., R. Cheung and P.K. Law. Acupuncture reduces electrophysiological and behavioral responses to noxious stimuli. Exp. Neurol. 54:172–178, 1977.
  10. Law, P.K. “Myotrophic” influences on motoneurons of normal and dystrophic mice in parabiosis. Exp. Neurol. 54:444–452, 1977.
  11. Burch, T. and P.K. Law. Normal development of muscle fibers and motor endplates in dystrophic mice. Exp. Neurol. 58:570–574, 1978
  12. Borum, P.R., J.H. Park, P.K. Law., and R.I. Roelofs. Altered tissue carnitine levels in animals with hereditary muscular dystrophy. J. Neurol. Sci. 38:113–121, 1978.
  13. Law, P.K. Reduced regenerative capability of dystrophic mouse muscle. Exp. Neurol. 60:231–243, 1978.
  14. Roelofs, R.K., G.S. deArengo, P.K. Law, Kinsman and J.H. Park. Treatment of Duchenne muscular dystrophy with D, L-penicillamine: Results of a double-blind trial. Arch. Neurol. 36:266–268, 1979.
  15. Law, P.K. and J.L. Yap. New muscle transplant method produces normal twitch tension in dystrophic muscle. Muscle & Nerve 2:356–363, 1979.
  16. Law, P.K. “Leaky” membrane causes weakness in dystrophic soleus fibers. Adv. Physiol. Sci. 5:213–214, 1980.
  17. Burch, T.G., R.L. Prewitt, and P.K. Law. In vivo Morphometric analysis of muscle microcirculation in dystrophic mice. Muscle & Nerve 4:420–424, 1981.
  18. Law, P.K. Beneficial effects of transplanting normal limb-bud mesenchyme into dystrophic mouse muscle. Muscle & Nerve 5: 619–627, 1982.
  19. Saito, A., P.K. Law, and S. Fleischer. Study of neurotrophism with ultrastructure of normal/dystrophic parabiotic mice. Muscle & Nerve 6:14–28, 1983.
  20. Law, P.K., A. Saito, and S. Fleischer. Ultrastructural changes in muscle and motor end-plate of the dystrophic mouse. Exp. Neurol. 80:361–382, 1983.
  21. Florendo, J.A., J.F. Reger, and P.K. Law. Electrophysiologic differences between mouse extensor digitorum longus and soleus. Exp. Neurol. 82:404–412, 1983.
  22. Kang, E.S., M.T. Capaci, E.H. Kang, P.K. Law, and G, Crosby. Fatty acid metabolism and mitochondrial proteins in the C57BL/6J-dy2Jdy2J dystrophic mice. Comp. Biochem. Physiol. 83B:545–550, 1986.
  23. Law, P.K., T.G. Goodwin, and M.G. Wang. Normal myobast injections provide genetic treatment for murine dystrophy. Muscle & Nerve. 11:525–533, 1988.
  24. Law, P.K., T.G. Goodwin, and H.J. Li. Histoincompatible myoblast injection improves muscle structure and function of dystrophic mice. Transplant Proc., 20:1114–1119, 1988.
  25. Law, P.K., et al. Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy. Lancet, 336:114–115, 1990.
  26. Law, P.K., T.G. Goodwin, Q. Fang, M. Chen, H-J. Li, A. Florendo, D.S. Kirby. T.E. Bertorini, H.G. Herrod, and G.S. Golden. Myoblast transfer therapy for Duchenne muscular dystrophy. ACTA Pediat. Jap. 33:206–215 1991.
  27. Fang, Q.W., M. Chen, H.J. Li, T.G. Goodwin, and P.K. Law. Vital marker for muscle nuclei in myoblast transfer. Can. J. Physiol. Pharmacol. 69:45–53, 1991.
  28. Law, P.K., T.G. Goodwin, Q. Fang, V. Duggirala, J.A. Florendo,D.S. Kirby, M.B. Deering, H.J. Li, M. Chen, T.J. Yoo, J. Cornett, L.M. Li, and R. L. Holcomb. Long-Term improvement in muscle function, structure and biochemistry following myoblast transfer in DMD. Acta Cardiomiologica, 3:281–301, 1991.
  29. Chen, M., H.J. Li, Q.W. Fang, T.G. Goodwin, J.A. Florendo, and P.K. Law. Dystrophin cytochemistry in MDX mouse muscles injected with labeled normal myoblasts.Cell Transplantation 1:17–22, 1992.
  30. Law, P.K., T.G. Goodwin, Q. Fang, V. Duggirala, C. Larkin, J. A. Florendo, D.S. Kirby, M.B. Deering, H.J. Li, M. Chen, T.J. Yoo, J. Cornett, L.M. Li, A. Shirzad, T. Quinley, and R.L. Holcomb. Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. Cell Transplantation 1:235–244, 1992.
  31. Law, P.K. Myoblast transplantation. Science 257: 1329-30, 1992.
  32. Law, P.K.; Goodwin, T.G.; Fang, Q.; Chen, M.; Li, H.J.; Florendo, J.A.; Kirby, D.S. Myoblast transfer therapy for Duchenne muscular dystrophy. Adv. Clin. Neurosci. 2:463–470; 1992.
  33. Law, P.K. Myoblast transfer therapy. Lancet 341:247, 1993.
  34. Law, P.K., T.G. Goodwin, Q. Fang, M.B. Deering, V. Duggirala, C. Larkin,
    J.A. Florendo, D.S. Kirby, H.J. Li, M. Chen, J. Cornett, L. Li, A. Shirzad, T. Quinley, T.J. Yoo, R. Holcomb. Cell transplanation as an experimental treatment for Duchenne muscular dystrophy. Cell Transplantation 2:485-505, 1993.
  35. Law, P.K., T.G. Goodwin, Q. Fang, M.B. Deering, V. Duggirala, C. Larkin,
    J.A. Florendo, J. Cornett, L. Li, A. Shirzad, T. Quinley, T.J. Yoo, R. Holcomb. Whole body myoblast transfer. Transpl Proc 26:3381-3383, 1994.
  36. Law, P.K., H. Li, M. Chen, Q. Fang, T. Goodwin. Myoblast injection method regulates cell distribution and fusion. Transpl Proc 26:3417-3418, 1994.
  37. Fang Q., M. Chen, H.J. Li, J.A. Florendo, T.G. Goodwin, P.K. Law. MHC-I antigens on cultured human myoblasts. Transpl Proc 26:4067, 1994.
  38. Law, P.K., T.G. Goodwin, Q. Fang, M.B. Deering, V. Duggirala, C. Larkin, J.A. Florendo, J. Cornett, L. Li, A. Shirzad, T. Quinley, T.J. Yoo, R. Holcomb. Cell Transplantation in Duchenne muscular dystrophy. Exp. Neurol, 129:8, 1994.
  39. Law, P.K., T.G. Goodwin, Q. Fang, T.L. Hall, T. Quinley, G. Vastagh, V. Duggirala, C. Larkin, J.A. Florendo, L. Li, T. Jackson, T.J. Yoo, N. Chase, M. Neel, T. Krahn, R. Holcomb. First human myoblast transfer therapy continues to show dystrophin after six years. Cell Transplantation 6:95-100, 1997.
  40. Law, P.K., T.G. Goodwin, Q. Fang, T. Quinley, G. Vastagh, T. Hall, T. Jackson, M.B. Deering, V. Duggirala, C. Larkin, J.A. Florendo, L.M. Li, T.J. Yoo, N. Chase, M. Neel, T. Krahn, R.L. Holcomb. Human Gene Therapy with Myoblast Transfer. Transpl Proc 29:2234-2237, 1997.
  41. Law, P.K., T.G. Goodwin, Q. Fang, G. Vastagh, T. Jordan, T. Jackson, S. Kenny, V. Duggirala, C. Larkin, N. Chase, W. Phillips, G. Williams, M. Neel, T. Krahn, R. Holcomb. Myoblast transfer as a platform technology of gene therapy. Gene Therapy and Molecular Biology 1:345-363, 1998.
  42. Law, P.K., Myoblast transfer as a platform technology of gene therapy. Regulatory Affairs Focus: Technology 4:25-27, 1999.
  43. Law P, Weinstein J, Ben Hain S et al. World’s first human myoblast transfer into the heart. Frontiers in Physiology 2000; A85.           
  44. Law P, Weinstein J, Ben Hain S et al. World’s first human myoblast transfer into the heart. Acta Physiol Scand 2000; A1-A114.
  45. Law, P.K., Nuclear Transfer and Human Genome Therapy. Business Briefing: Future Drug Discovery Genomics: 38-42, December 2001.
  46. Law PK, Haider Kh., Fang G et al. Mechanisms of myoblast transfer in treating heart failure (2002) In: Kimchi, A., Ed., Advances in Heart Failure, Medimont, 43-48.
  47. Law, P.K., The Regenerative Heart. Business Briefing: PharmaTech 2002 Drug Discovery: 65-71, April 2002.
  48. Law, P.K., Concomitant Angiogenesis/Myogenesis in the Regenerative Heart. Business Briefing: Future Drug Discovery, Genomics: 64-67, October 2002.
  49. Haider Kh H., Ye L., Jiang SJ., Law PK and Sim EKW. Avoiding compliance with histocompatibility dogma using immune privileged cell xenografts. Ann Thorac Surg 2003; 76:339-40.
  50. Sim EKW, Haider Kh H., and Law PK. Single fiber skeletal muscle    transplantation or purified myoblast engraftment? J Thoracic Cardiovasc Surgery   2003;125:5.
  51. Haider Kh H., Ye L., Jiang SJ., Law PK., Sim EKW. Myoblast transplantation for      cardiac repair using transient immunosuppression. Basic Appl Myol 2003,13(1): 45-52.
  52. Haider HKh. , Jiang S, Ye L, Law P K and Sim EKW. Human skeletal myoblasts: potential for improving outcome of patients with end-Stage heart failure. ASEAN Heart Journal 2003; 10:1.
  53. Law, P. K., Fang, G., Chua, F., Kakuchaya, T., and Bockeria, L. A. (2003). First-      in-Man myoblast allografts for heart degeneration. Int. J. Med. Implants Devices 1: 100 – 155.
    Ye L, Haider KH, Jiang SJ, Ling LH, Niagara MI, Rufaihah AJ, Law PK, Sim            EK. Angiomyogenesis using human myoblast carrying human VEGF165 for          injured heart. Ann Acad Med Singapore. 2003, 32:S21-3.
    Ye L, Haider HKh, Jiang S, Ge R, Law PK, Sim EK.High efficiency transduction      of human VEGF165 into human skeletal myoblasts: in vitro studies. Exp Mol   Med. 2003, 35:412-20.
  54. Haider HKh, Lei Y, Jiang S, Law PK, Sim EK .Avoiding compliance with      histocompatibility dogma using immune privileged cell xenografts. Ann Thorac          Surg. 2003,76:339-40.
  55. Sim EK, Haider HK, Law PK. Single fiber skeletal muscle transplantation or purified myoblast engraftment? J Thorac Cardiovasc Surg. 2003,125:1181-2.
    Law PK, Haider K, Fang G, Jiang S, Chua F, Lim YT, Sim E. Human             VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the           regenerative heart. Mol Cell Biochem 2004, 263:173-8.
    Law PK , Law DLM , Lu P, Guo J, Lu Y, Xue YF, and Li X. The world’s first           myoblast study of Type II diabetic patients。 Business Briefing: North American            Pharmacotherapy 2004-Issue 2
    Haider HKh, Ye L, Jiang S, Ge R, Law PK, Chua T, Wong P, Sim EK.          Angiomyogenesis for cardiac repair using human myoblasts as carriers of human            vascular endothelial growth factor. J Mol Med. 2004, 82:539-49.
  56. Haider HKh, Jiang SJ, Ye L, Aziz S, Law PK, Sim EK. Effectiveness of transient immunosuppression using cyclosporine for xenomyoblast transplantation for      cardiac repair. Transplant Proc. 2004, 36:232-5.
  57. Haider Husnain Kh; Ye Lei; Jiang Shujia; Ge Ruowen; Law Peter K; Chua     Terrance; Wong Phillip; Sim Eugene K W. Angiomyogenesis for cardiac repair       using human myoblasts as carriers of human vascular endothelial growth factor. J Mol Med 2004;82:539-49.
  58. Haider Husnain Kh; Ye Lei; Jiang Shujia; Law Peter K; Sim Eugene K W.      Immunosuppression and xenotransplantation of cells for cardiac repair. The     Ann Thorac Surg 2004;77(3):1133; author reply 1133-4.
  59. Ye L, Haider HKh, Jiang S, Ling LH, Ge R, Law PK, Sim EK. Reversal of     myocardial injury using genetically modulated human skeletal myoblasts in a        rodent cryoinjured heart model. Eur J Heart Fail. 2005, 7:945-52.
  60. YeL, Haider HKh, Jiang S, Ge R, Law PK, Sim EK. In vitro functional         assessment of human skeletal myoblasts after transduction with adenoviral   bicistronic vector carrying human VEGF165 and angiopoietin-1. J Heart Lung    Transplant. 2005, 24: 1393-402.
  61. Sim Eugene K W; Haider Husnain K H; Aziz Salim; Ooi Oon C; Law Peter K.           Myoblast transplantation on the beating heart. Internat Surg       2005;90:148-50.
  62. Deng W, Ye Lei, Esa WB , Haider Kh H, Ratha M, Law PK, Lim YT, Teh M, Sim EKW. Liposome Mediated Gene Delivery System Using Human Skeletal Myoblasts. Proceedings of the International Federation for Medical and Biological Engineering 2005; 12: 1B2-05.
  63. Law PK, Law DL, Lu P, Sim EKW, Haider Kh H, Ye Lei, Li X, Vakhromeeva MN, Berishvili II, Bockeria LA, Liew CC. Human myoblast genome therapy. J Geriat Cardiol 2006; 3(3): 135-151.
  64. Ye Lei, Haider Kh H, Jiang SJ, Tan RS, Song IC, Ge RW, Law PK, Sim EKW. Skeletal myoblast based delivery of angiogenic growth factors: a comparison between angiopoietin-1 and VEGF gene delivery for therapeutic angiogenesis in the heart. J Geriat Cardiol 2006; 3(3): 152-160.
  65. Law, P.K.; Goodwin, T.G.; Fang, Q.; Chen, M.; Li, H.J.; Florendo, J.A.; Kirby, D.S. Myoblast transfer therapy for Duchenne muscular dystrophy. Pediatr Int 2007 ; 33:206-15.
  66. Law P K, Law DM, Lu P. Anti-aging aesthetica (AAA): Beautiful and strong forever. www.njscrefcharm.org/ejournal/lawantiaging307.html, 2007.
  67. Ye Lei; Haider Husnain Kh; Jiang Shujia; Tan Ru San; Ge Ruowen; Law Peter K;      Sim Eugene K W. Improved angiogenic response in pig heart following ischaemic         injury using human skeletal myoblast simultaneously expressing VEGF165 and        angiopoietin-1. Eur J Heart Fail 2007;9: 15-22.
  68. Ye Lei; Haider Husnain Kh; Tan RuSan; Toh WeeChi; Law Peter K; Tan       WeeBeng; Su LiPing; Zhang Wei; Ge RuoWen; Zhang Yong; Lim YeanTeng;     Sim Eugene K W. Transplantation of nanoparticle transfected skeletal myoblasts        overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 2007;116:I113-20.
  69. Guo Changfa; Haider Husnain Kh; Shim Winston S N; Tan Ru-San; Ye Lei; Jiang Shujia; Law Peter K; Wong Philip; Sim Eugene K W. Myoblast-based cardiac repair: xenomyoblast versus allomyoblast transplantation. J Thorac Cardiovasc Surg 2007;134(5):1332-9.
  70. Ye Lei; Haider Husnain Kh; Esa Wahidah Bte; Law Peter K; Zhang Wei; Su LiPing; Zhang Yong; Sim Eugene K W. Nonviral vector-based gene transfection            of primary human skeletal myoblasts. Exp Biol Med 2007;232:1477-87.
  71. Ye Lei; Haider Husnain Kh; Tan RuSan; Su LiPing; Law Peter K; Zhang Wei;            Sim Eugene K W. Angiomyogenesis using liposome based vascular endothelial growth factor-165 transfection with skeletal myoblast for cardiac repair. Biomaterials 2008;29:2125-37.
  72. Ye L; Lee K O; Su L P; Toh W C; Haider H K; Law P K; Zhang W; Chan S P;            Sim E K W. Skeletal myoblast transplantation for attenuation of hyperglycaemia,   hyperinsulinaemia and glucose intolerance in a mouse model of type 2 diabetes         mellitus. Diabetologia 2009;52:1925-34.
  73. Ye Lei, Haider KhH, Esa WB, Su LP, Law PK, Zhang W, Lim YT, Poh KK, Sim EKW. Liposome-based vascular endothelial growth factor-165 transfection with skeletal myoblast for treatment of ischaemic limb disease. Journal of Cellular and Molecular Medicine 2010; 14: 323-336.
  74. Law P K and Law DM. Human Myoblast Genome Therapies and Devices in Regenerative Medicine. Rec Pat Regen Med 2011; 1: 88-117.
  75. Law PK, Li Y, Haider HKh, Lu P, Law DM, Sim EKW. Therapeutic angiomyogenesis using human non-viral transduced VEGF165- myoblasts. Open J Regen Med 1:1-9, 2012.   
  76. Ye L, Su L-P, Pi WF, Law PK. Role of Thymosin β4 on skeletal myoblast migration, proliferation, and Survival. Rec Pat Regen Med 2012,2:146-155.
  77. Ma J-H, Su L-P , Zhu J ,Law PK ,Lee K-O , Ye L, Wang ZZ. . Skeletal myoblast transplantation on gene expression profiles of insulin signaling pathway and mitochondrial biogenesis and function in skeletal muscle. Diabetes Res Clin Pr 102: 43-52, 2013.            
  78. Law PK. Disease prevention and alleviation by myoblast transplantation. Open J. Regen. Med. 5: 25-43, 2016.
  79. Law PK, Song SJ, Lu P, Gao Y, Ao M, Zhao H, Bai L, Guo K, Law DM. World’s first myoblast treatment of human cancer found safe and efficacious. Open J Regen Med. 6:1-16, 2017.
  80. Cheng W, Law PK. Conceptual design and procedure for an autonomous intramyocardial injection catheter. Cell Transplantation 26:735-751,2017.
  81. Cheng W, Law PK. Feedforward coordinate control of a robotic cell injection catheter. Cell Transplantation 2017, in press.

transplantation-research Journal Flyer